All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
TAE Life Sciences, Ohio State University partner to advance precision cancer therapy
The partnership aims to develop and evaluate novel boron-based compounds, crucial for Boron Neutron Capture Therapy (BNCT), marking a significant step in precision oncology.
Concentra to acquire small-molecule therapeutics maker Kronos Bio
Kronos Bio is a biopharmaceutical company developing small-molecule therapeutics targeting cancer and autoimmune diseases
Lilly reports 23% increase in Q1 2025 net income to $2.76bn
Lilly attributed the revenue growth to a 53% increase in volume, which was partially offset by lower realised prices and unfavourable impact from foreign exchange rates.
Novartis to acquire Regulus Therapeutics for up to $1.7bn
The acquisition includes Regulus’ lead asset, farabursen, an investigational microRNA inhibitor targeting miR-17 with preferential kidney exposure, to reduce cyst growth and kidney size
J&J’s Imaavy granted FDA approval for generalised myasthenia gravis
Imaavy is a monoclonal antibody designed to block FcRn with high affinity and reduce levels of circulating immunoglobulin G (IgG) antibodies, without affecting other immune functions
AbbVie secures FDA approval for Rinvoq to treat giant cell arteritis
The FDA approval of Rinvoq is supported by the results from the Phase 3 SELECT-GCA clinical trial, which met its primary endpoint of sustained remission in GCA patients
Filspari granted EC standard authorisation to treat IgA nephropathy
The EC approval, which transitions Filspari’s status from conditional authorisation to standard, follows the European Medicines Agency’s CHMP recommendation.
Merck to acquire US-based biotech firm SpringWorks for $3.9bn
Merck will purchase SpringWorks’ shares at $47 each, translating to an equity value of around $3.9bn, and will finance the acquisition through available cash and new debt
Krystal Biotech secures EC approval for Vyjuvek to treat rare genetic disorder
Vyjuvek is a gene therapy that uses a herpes-simplex virus type 1 (HSV-1) vector to deliver functional copies of the human COL7A1 gene, to address the genetic root cause of DEB
Thermo Fisher Scientific Leverages Integrated Solutions to Accelerate the Development of Biologic Therapeutics
Enhanced platform technology and the addition of a robust, high-quality CHO K-1 cell line decreases lead time to Investigational New Drug (IND)